Zhang Dan successively received a doctor of medicine from Peking Union Medical College, a master of public health from Harvard University, and a master's degree in medical management from the Wharton School of the University of Pennsylvania. Zhang Dan was the world’s largest multinational CRO (Quintiles Transnational Corp.) and the first chairman of the Greater China region. He successfully created the Greater China market. Later, he created a CRO company dedicated to the international development of innovative drugs. En Medicine. Zhang Dan is the leader of the International ICH E19 IFPMA Expert Committee and an expert of the NMPA ICH Working Group. He used to be the president of the American-Chinese Biomedical Technology Association (CBA), the executive director of the American-Chinese Pharmaceutical Professional Association (SAPA), and the director of the BayHelix Association (BayHelix). He used to be the responsible expert for the national "Eleventh Five-Year Plan" and "Twelfth Five-Year Plan" major new drug creation plan, and participated in the formulation of technical guidelines and the clinical review of new drugs and the training of drug review personnel of the Drug Evaluation Center of the State Drug Administration.

Established in 1990, the Russian Academy of Engineering is one of the three major cross-industry scientific institutions in Russia. The first dean was Prokhov, a famous Russian scientist, Nobel Prize winner, and academician of the Russian Academy of Sciences. Currently, the Academy has more than 1,500 academicians, including more than 100 foreign academicians. Famous scientists such as Song Jian, former vice chairman of the Chinese People's Political Consultative Conference, academician of the Chinese Academy of Sciences and Chinese Academy of Engineering, Xu Kuangdi, president of the Chinese Academy of Engineering, Zhai Yusheng, president of China University of Geosciences, and Ge Shirong, president of China University of Mining and Technology, have also won this honor.

Zhang Dan said: my country's biopharmaceutical industry production and research standards will gradually embrace internationalization, and domestically produced innovative drugs will gradually enter the world, and gradually absorb high-level innovative scientific research technologies and enterprises from around the world with a more open attitude. Pingshan District is at the forefront of the international and domestic "dual cycle" strategy. It has a broad international cooperation market and is convenient for international talent recruitment. In addition, the establishment of a number of biomedical field funds and the implementation of supporting innovation platforms have made Pingshan District become a driving force for China. The fulcrum of the international development of the biomedical industry.

Recently, Zhang Dan, as a consultant to the Shenzhen Pingshan District Committee and District Government, explained to leaders at all levels the construction process of the International Academy of Medical Sciences and the Medical Transformation Center, helping to lay a solid foundation for the development of the Pingshan Biomedical Industrial Park. In the future, Zhang Dan will lead the team to build the Pingshan ICH Park that meets international standards, build an international talent system that meets ICH standards, and provide strong support for building a new highland for the biomedical industry in the Guangdong-Hong Kong-Macao Greater Bay Area.

As the eastern center of Shenzhen, the core park of the Shenzhen National High-tech Zone and the Shenzhen Future Industrial Pilot Zone, Pingshan has the first batch of national bio-industry bases in Shenzhen and the only national-level bio-industry base in Shenzhen. Major projects such as the Pingshan Biomedicine R&D and Transformation Center and the Hong Kong Famous Doctor's Diagnosis and Treatment Center have settled in the new mechanism of the Academy of Medical Sciences, and the first applied pharmacy school in the Guangdong-Hong Kong-Macao Greater Bay Area-Shenzhen University of Technology School of Pharmacy and other high-end innovation platforms , Held high-level, internationally innovative brand activities such as the BT Summit, the Greater Bay Area Vaccine Summit, and the Deep Innovation Competition. The number of enterprises and the total output value of the industry have maintained a growth rate of about 30% for many years. It has gathered a large number of star companies such as Sanofi Pasteur and New Industries, forming a good situation of Pingshan being the first choice for biomedical companies.

Future Pingshan ICH Biomedical Industrial Park

Will gather and link high-quality biomedical companies at home and abroad

Produce agglomeration effect of biomedical industry

Build Pingshan ICH Biomedicine Industrial Park

International premium brand

Let Pingshan go out of Shenzhen, go out of the country, and go international